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Consult Your Pharmacist

New Statin Risks
and the Battle for OTC Status

T

he prescription-tononprescription switch
process is a dynamic
movement that has radically
expanded the number of medical
conditions for which consumers can
self-medicate. Recent Rx-to-OTC
switches include products for
gastroesophageal reflux, overactive
bladder in women, weight loss, and
allergic conjunctivitis. However, the
goal of moving cholesterol-lowering
medications to nonprescription
status has been elusive, despite
vigorous efforts initiated by the
manufacturers of these products.

The Push Begins
In 1997, the FDA revealed that
“several sponsors” had approached
the agency about the possibility of
marketing nonprescription medica
tions for hypercholesterolemia.1 In
response, the FDA stated that its
Center for Drug Evaluation and
Research (CDER) had determined
that nonprescription status would
not be appropriate. The FDA also
announced the availability of a
newly created guidance document
that reflected its thinking on the
issue. This document stated that
hypercholesterolemia is a “chronic,
asymptomatic condition” that
requires an “accurate diagnosis,
risk assessment, and potentially
clinical testing to prevent athero
sclerotic cardiovascular disease, and
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Statins low er ch olesterol levels by in h ib itin g the enzym e HMG-CoA reductase, w hich
plays a cen tra l role in the p ro d u ction o f ch olesterol in the liver.

that the medical management
should be directed by a healthcare
professional.”2

The 2000 FDA Meeting
On June 1, 2000, the FDA
announced that it had scheduled a
joint meeting of the Nonprescription
Drugs Advisory Committee and
the Endocrinologic and Metabolic
Drugs Advisory Committee.3 The
meeting would consider two New
Drug Applications (NDAs) submit
ted in 1999.2 Merck proposed to
switch Mevacor (lovastatin 10 mg)
to OTC status, and Bristol-Myers
Squibb wished to switch Pravachol
(pravastatin 10 mg). In both cases,
the patents were nearing their
expiration date, and moving the
products to nonprescription status
could have extended the patent life
for a few additional years.4 Both
manufacturers sought approval

for treating patients with total choles
terol levels of 200 to 240 mg/dL and
low-density lipoprotein (LDL) levels
>130 mg/dL. Mevacor would have
been labeled for men aged >40 years
and postmenopausal women who
did not have established cardiovas
cular disease or diabetes. Pravachol
would have been labeled for individ
uals who did not have established
cardiovascular disease or diabetes.
The FDA presented a set of slides
for each NDA concluding that
nonprescription status would not
be appropriate, for a variety of
reasons.5,6 Among the deficiencies
and remaining questions in one or
both studies were: 1) concerns that a
10-mg dose of lovastatin might not
be effective in altering lipids in the
target population; 2) the study popu
lation was not representative of the
overall U.S. population; 3) there
was low consumer understanding of
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specific serum cholesterol values; 4)
patients in the study made a substan
tial number of self-selection errors;
5) there was poor adherence to
therapy; and 6) significant numbers
of patients may not understand
who should not use the products.2
Ultimately, committee members
concluded that consumers would not
be able to safely and appropriately
self-manage hypercholesterolemia.

Guidance Document Withdrawn
Even though the outcome of the
2000 meeting was negative, the
FDA recognized that “the public
interest in the availability of safe
and effective therapies to treat
hypercholesterolemia warranted
communication between FDA and
industry to evaluate the feasibility
of such therapies O TC.”2 Therefore,
the FDA withdrew the guidance
document, allowing the issue to be
explored further. The FDA also sent
a detailed letter to Merck describing
the many deficiencies in its NDA
for the lovastatin switch.2

The 2004 Lovastatin Resubmission
Apparently, Merck did not view the
matter as closed. The manufacturer
resubmitted its NDA in 2004,
addressing the deficiencies listed by
the FDA.2 The proposed dosage was
raised to 20 mg of lovastatin. Merck
also published the results of the
Consumer Use Study of OTC
Mevacor (CUSTOM).7 This actual
use study found that a multifaceted
cholesterol self-management program
was effective in allowing patients to
self-identify and safely use nonpre
scription lovastatin 20 mg. In
response, the FDA announced
another joint meeting of the same
two committees to consider the
switch of Mevacor for January 2005.8

Pharmacy Support Builds
Built into the 2004 resubmission
was a proposal from Merck that
lovastatin be dispensed only by
pharmacists.9 This required Merck
to solicit the support of pharmacists
for the switch. Major support arose
in the American Pharmacists
Association (APhA). The APhA
began to speak of a “Pharmacy Care
O TC” class of medications. The
APhA created a task force to address
the issue and presented its findings
to the 2005 FDA meeting.10,11 The
remarks to the FDA meeting specif
ically spoke to lovastatin. W hile the
stated mission of the task force was
not limited to lovastatin, it is critical
to note that the APhA apparently
ceased its efforts to support the
Pharmacy Care OTC category
(at least under that name) after an
FDA denial for the lovastatin switch
appeared to be inevitable.

The 2005 FDA Meeting
At the 2005 meeting, committee
members expressed concern that
there were insufficient data regarding
efficacy of a 20-mg dose of lovastatin
when compared to usual care.2
Furthermore, the results of the
CUSTOM study were judged
inadequate to support nonprescrip
tion sales of lovastatin. The FDA
sent a letter to Merck detailing many
deficiencies in its resubmission and
denied the application. One member
of the committee was quoted as
stating that the CUSTOM study
was a “failed study,” adding that it
was unconvincing.12

The 2007 Lovastatin Resubmission
Merck still saw a chance for OTC
lovastatin. The manufacturer
conducted two label comprehension
studies; designed and carried out a

self-selection study (known as the
SELECT study); and amassed
additional safety data, including an
examination of safety in patients
with underlying hepatic disease.2
Merck also included a preliminary
copy of a nonprescription package,
complete with consumer labeling
for the product, to be known as
Mevacor OTC.2

The 2007 FDA Meeting
On October 23, 2007, the FDA
announced that it would once again
convene the two committees to
consider the Merck submission at a
meeting to be held on December
13, 2007.13 News sources reported
that the outcome was negative.14
Apparently, in a study examining
consumer behavior, 25% of people
who wished to purchase Mevacor
OTC had cholesterol levels so low
that they were not at risk for heart
disease. Even more compelling,
30% of people who were high-risk
(having heart disease, diabetes, or
stroke) wished to purchase Mevacor
OTC, even though they should have
chosen to seek the care of a physi
cian. Additionally, 30% of patients
already taking a stronger version of
a prescription statin said they would
stop taking that prescription statin
and begin self-treatment with lowdose Mevacor OTC. The committee
was concerned that this last group
of patients would sacrifice proven
protection and be at higher risk for
heart attack.

Recent FDA Consumer Warnings
It is entirely possible that statin
manufacturers still entertain hopes
of gaining nonprescription status
(see SIDEBAR), even though the
matter appears to have been
dormant since 2007. For this
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Is There a Future for OTC Lipitor?
Lipitor (atorvastatin) was once the top-selling medication in the U.S., but sales nosedived
when the generic version became available several years ago. The drug's manufacturer,
Pfizer, is actively exploring an OTC switch for Lipitor in an effort to regain lost sales. The
company enrolled 1,200 patients in a study to determine their ability to self-manage
LDL-cholesterol with OTC Lipitor 10 mg.18 Patients would be responsible for obtaining
blood tests and making therapeutic decisions based on their results. If study outcomes
proved to be positive, Pfizer would proceed with its FDA submission. The FDA website
does not show such a submission at this time, so the matter may still be under consideration.

reason, it is instructive to examine
recent FDA publications regarding
statins. In early 2014, the FDA
addressed several statin risks in a
paper directed to consumers and
professionals.15 The agency stressed
that package inserts would be
revised to reflect any changes.
For example, liver injury was
characterized as a possible but rare
risk of statin use. The FDA once
required labeling recommending
that statin users have regular liver
enzyme tests. That warning was
revised to recommend testing before
beginning statin use and then as
needed if there are symptoms of
hepatic damage (e.g., unusual
fatigue, anorexia, right upper
abdominal discomfort, dark urine,
jaundice of the skin or eyes).
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The FDA also warned consumers
that statins can cause memory loss,
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there is an increased risk of myopa
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cataract warning about statins.16 It
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that appeared in the Canadian
Journal o f Cardiology}17Researchers
examined databases of statin users
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Columbia) and 11 years (U.S.);
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were included. Among those who
had taken statins for >1 year, the
increased risk of developing cataracts
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of ceasing to take them.16 ■
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PATIENT INFORMATION
How to Fight High Cholesterol

It is now common knowledge that there is a
firm link between high cholesterol and heart
disease. It is hard to know i f you have high

If you are worried about your risk
for heart disease and wish to
explore the possibility of high
cholesterol, there are some actions
you can take.

Ask Your Physician
for a Blood Test
The first step is to ask your
physician for a blood test to
determ ine your blood cholesterol.
The exam is known as a lip op ro
tein p ro file, and its purpose is to
measure four markers: 1) total
cholesterol, w hich should be
below 200 mg/dl; 2) LDL or
“bad” cholesterol, w hich should
be less than 100 mg/dL; 3) HDL
or “good” cholesterol), w hich
should be 40 mg/dL or above;
and 4) triglycerides, w hich should
be less than 150 mg/dL. If your
values are out of the normal
range, your physician can create
a treatm ent plan for you.

Begin a Healthy Diet
One of the prim ary risk factors
for high cholesterol is a poor diet
that results in obesity. Eating
heathier foods has been proven
to lower cholesterol. It is critical
to avoid saturated fats, trans
fats, and dietary cholesterol.
Saturated fats are found in the
following foods (w hich should be

m inim ized as m uch as possible or
avoided com pletely): high-fat
cheese, high-fat m eat cuts, whole
m ilk, cream, butter, ice cream,
palm oil, and coconut oil. To
m inim ize trans fats, avoid fatty
m eat and dairy products (as
above), and also hydrogenated
oils. D ietary cholesterol is found
in meat, poultry, egg yolks, and
whole m ilk. The best advice for
all of these issues is to switch to
a low-fat diet and ingest only fatfree dairy products. Eating foods
high in fiber can lower cholesterol
as well.

Healthy Lifestyle Tips
There are several other lifestyle
tips to keep cholesterol down and
increase your chances of living
a long, healthy life. Avoiding
alcohol is im portant, as this can
also keep triglycerides down. If
you smoke, it is critical that you
q u it im m ediately. Sm oking is
dam aging to your blood vessels,
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cholesterol, since it seldom causes any symptoms.
speeding the process of hardening
of the arteries. If you stop
sm oking, you lower your risk
of heart disease and stroke. A
sedentary lifestyle is a major risk
factor for high cholesterol. To
combat this problem, begin an
exercise program. Start slowly,
w ith advice from your physician.
In addition, if you also have
diabetes or high blood pressure,
follow your physician’s advice to
control these conditions.

Common Cholesterol-Lowering
Medications
You cannot self-treat high choles
terol by taking nonprescription
products, no m atter w hat the
advertisements promise. In fact,
no herbal supplem ent or vitam in
is safe or effective for this use.
However, there are several
m edications that your physician
can prescribe. The most common
is the group known as the statins.
They include atorvastatin (Lipitor),
lovastatin (Mevacor), pravastatin
(Pravachol), rosuvastatin (Crestor),
and sim vastatin (Zocor). Statins
block one of the chem icals your
body needs to make cholesterol.
These drugs are generally safe,
and your pharm acist or physician
can explain the risks of their
use. ■

Rem ember, i f y o u h a ve questions, Consult Your Pharm acist.
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